Compare Neurocrine Biosciences Inc (NBIX) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Zillow Group Inc Class A — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Zillow Group Inc Class A trades at $32.92 (market cap $7.31B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.2× Zillow Group Inc Class A's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals.
| NBIX | ZG | |
|---|---|---|
Market Cap | $15.77B | $7.31B |
Sector | Health | Media |
52-Week High | $185.50 | $86.76 |
52-Week Low | $123.10 | $29.14 |
Enterprise Value | $15.78B | $7.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Zillow Group (ZG) trades at $33.03, down 6.48% in the last session, with technical indicators showing a bearish trend as the price approaches key support near $32. Fundamentally, the company shows improving revenue growth to $2.58 billion in 2025 and a return to profitability with net income of $23 million, though valuation remains elevated with a P/E of 143.57. Recent news highlights Zillow's strategic shift to an integrated transaction platform and resolution of FTC litigation.
The outlook is mixed: analyst consensus targets $47.56 (44% upside) with 47% buy ratings, but near-term housing market softness and high valuation pose risks. The stock offers growth potential through platform monetization, yet investors face execution risks and macroeconomic headwinds in the real estate sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
